Literature DB >> 33546154

Markers of Cellular Proliferation, Apoptosis, Estrogen/Progesterone Receptor Expression and Fibrosis in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids.

Iwona Szydłowska1, Marta Grabowska2, Jolanta Nawrocka-Rutkowska1, Małgorzata Piasecka2, Andrzej Starczewski1.   

Abstract

There appear to be very few data on the exact mechanisms of a selective progesterone receptor modulator action in myomas. The aim of the study was to assess the effects of ulipristal acetate (UPA) on fibroids, especially on estrogen receptor (ER) and progesterone receptor (PR) immunoexpression, proliferation, apoptosis and tissue fibrosis, and to compare the above parameters in untreated (surgical attention only) and UPA-treated leiomyomas. UPA-treated patients were divided into three groups: (1) good response (≥25% reduction in volume of fibroid), (2) weak response (insignificant volume reduction) and (3) no response to treatment (no decrease or increase in fibroid volume). The study observed a significant decrease in the percentage of collagen volume fraction and ER and PR immunoexpression in the good response group, in the percentage of proliferating cell nuclear antigen (PCNA)- and Ki67-positive cells in the groups with good and weak reactions vs. control group; significantly higher apoptotic index (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells) in the good reaction group vs. control group. The results of the study indicate that a good response to UPA, manifested by a volume reduction of myoma, may be associated with a decrease in fibrosis, ER/PR and PCNA and Ki67 immunoexpression and an increase in cell apoptosis within the myoma.

Entities:  

Keywords:  apoptosis; estrogen receptor; fibrosis; progesterone receptor; proliferation; ulipristal acetate; uterine myoma

Year:  2021        PMID: 33546154      PMCID: PMC7913139          DOI: 10.3390/jcm10040562

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  35 in total

Review 1.  Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics.

Authors:  Md Soriful Islam; Andrea Ciavattini; Felice Petraglia; Mario Castellucci; Pasquapina Ciarmela
Journal:  Hum Reprod Update       Date:  2018-01-01       Impact factor: 15.610

2.  In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment.

Authors:  Guillaume E Courtoy; Jacques Donnez; Etienne Marbaix; Marie-Madeleine Dolmans
Journal:  Fertil Steril       Date:  2015-05-21       Impact factor: 7.329

3.  Protein expression of estrogen receptors α and β and aromatase in myometrium and uterine leiomyoma.

Authors:  Anelise Olmos Grings; Vanessa Lora; Gustavo Dias Ferreira; Ilma Simoni Brum; Helena von Eye Corleta; Edison Capp
Journal:  Gynecol Obstet Invest       Date:  2012-02-22       Impact factor: 2.031

4.  Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.

Authors:  K Vu; D L Greenspan; T C Wu; H A Zacur; R J Kurman
Journal:  Hum Pathol       Date:  1998-04       Impact factor: 3.466

Review 5.  Selective progesterone receptor modulators: an update.

Authors:  Giuseppe Benagiano; Carlo Bastianelli; Manuela Farris; Ivo Brosens
Journal:  Expert Opin Pharmacother       Date:  2014-04-30       Impact factor: 3.889

6.  The FIGO classification of causes of abnormal uterine bleeding in the reproductive years.

Authors:  Malcolm G Munro; Hilary O D Critchley; Ian S Fraser
Journal:  Fertil Steril       Date:  2011-04-15       Impact factor: 7.329

7.  Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.

Authors:  Khaleque Newaz Khan; Michio Kitajima; Koichi Hiraki; Akira Fujishita; Ichiro Sekine; Tadayuki Ishimaru; Hideaki Masuzaki
Journal:  Hum Reprod       Date:  2009-12-15       Impact factor: 6.918

Review 8.  The place of selective progesterone receptor modulators in myoma therapy.

Authors:  Jacques Donnez; Olivier Donnez; Guillaume E Courtoy; Marie M Dolmans
Journal:  Minerva Ginecol       Date:  2016-03-01

9.  Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.

Authors:  Youn-Jee Chung; Boah Chae; Se-Hyun Kwak; Jae-Yen Song; Ah-Won Lee; Hyun-Hee Jo; Young-Ok Lew; Jang-Heub Kim; Mee-Ran Kim
Journal:  Int J Med Sci       Date:  2014-01-28       Impact factor: 3.738

10.  Receptors of hypothalamic-pituitary-ovarian-axis hormone in uterine myomas.

Authors:  Danuta Plewka; Jacek Marczyński; Michał Morek; Edyta Bogunia; Andrzej Plewka
Journal:  Biomed Res Int       Date:  2014-06-22       Impact factor: 3.411

View more
  2 in total

Review 1.  Dietary Natural Compounds and Vitamins as Potential Cofactors in Uterine Fibroids Growth and Development.

Authors:  Iwona Szydłowska; Jolanta Nawrocka-Rutkowska; Agnieszka Brodowska; Aleksandra Marciniak; Andrzej Starczewski; Małgorzata Szczuko
Journal:  Nutrients       Date:  2022-02-09       Impact factor: 5.717

2.  Ultrasound-guided HIFU for uterine fibroids of hyperintense on T2-weighted MR imaging with or without GnRH-analogue-pretreated: A propensity score matched cohort study.

Authors:  Li Jiang; Jing-Wen Yu; Mei-Jie Yang; Qiao Zhong; Jin-Yun Chen
Journal:  Front Surg       Date:  2022-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.